Comparative Pharmacology
Head-to-head clinical analysis: FERABRIGHT versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERABRIGHT versus SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE.
FERABRIGHT vs SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy: provides elemental iron for erythropoiesis, correcting iron deficiency anemia.
Sodium ferric gluconate complex in sucrose provides elemental iron for hemoglobin synthesis and replenishes iron stores in iron-deficient states. The iron complex is taken up by the reticuloendothelial system, where iron is released and bound to transferrin for erythropoiesis.
Intravenous bolus of 100 mg ferric carboxymaltose (elemental iron), administered no more than 3 times per week until iron repletion is achieved.
125 mg elemental iron (10 mL) intravenously over at least 10 minutes, given at sequential dialysis sessions to a cumulative total dose of 1000 mg elemental iron.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal elimination half-life is approximately 6 hours for the iron-sucrose complex; clinical context: indicates redistribution and utilization for erythropoiesis, with full hemoglobin correction over weeks.
Renal elimination of unchanged drug accounts for approximately 60-70% of total clearance, with biliary/fecal excretion contributing 20-30%. The remainder undergoes hepatic metabolism.
Primarily excreted via feces (93%) as non-absorbed iron; renal elimination of absorbed iron is minimal (<1%).
Category C
Category C
Iron Supplement
Iron Supplement